The number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Brazil has been projected to increase annually from 2024 to 2028, starting at 1.28 thousand cases in 2024 and reaching 1.47 thousand by 2028. Comparing these projected figures against the actual data from previous years shows a growing trend, although the baseline figure from 2023 remains unspecified. Year-on-year, the percentage increase is a steady 3.9% across each subsequent year. Therefore, the compound annual growth rate (CAGR) over this five-year period is approximately 3.9% as well.
Future trends to monitor include the impact of healthcare interventions aimed at reducing TB incidence, the introduction of new treatment protocols or vaccines, and broader social determinants such as healthcare access, poverty reduction, and public health awareness campaigns, all of which could significantly alter these projections. Additionally, monitoring potential new strains and resistance patterns will be critical in adapting strategies to manage TB effectively.
